Diagnostics company Clarient has added to its molecular testing portfolio by acquiring Applied Genomics (AGI) for $17.6m. The all-stock merger permits Clarient access to AGI’s technology for detecting cancer. These products include Pulmotype, a lung cancer test scheduled for ...
Please Login to read the full article.
